Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
TOP SEARCHES: OCT // Canaloplasty // AMD
In this issue
Circle lenses
AMD
SBK
Alcon acquisition
Gene technology
Survey

Will you be attending ESCRS this year?

Yes 29%
No 33%
Not yet decided 38%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Pamela Brook, editor.

Click here to contact Neil Hanley, sales manager.

July 14, 2010


Concerns raised about Lady Gaga inspired circle lenses
The American Academy of Ophthalmology has issued a warning about the harm decorative circle lenses used by Lady Gaga in a recent video. Her wide-eyed doll look has been mimicked by her fans. More...
Implantable telescope finally gets FDA approval
VisionCare's implantable telescope for end-stage AMD has finally been given FDA approval. The device, discussed in depth in Ophthalmology Times Europe July 2007, was given CE approval three years ago but has subsequently been undergoing rigorous clinical trials in the United States.The pivotal clinical trial showed that patients achieved clinically meaningful gains in visual acuity and quality of life with the telescope implant. More...
Leading Chinese KOL puts microkeratomes through their paces
Professor Ye-Guo Chen, one of the top five key opinion leaders in Chinese refractive surgery has demonstrated a drastic improvement in flap thickness and planarity when using the One Use-Plus SBK microkeratome, defined as 'Sub Bowman's Keratomileusis. ' More...
Product Profile
Carl Zeiss Meditec
IOLMaster® 500 - With automatic and non-contact measurement of the patient's eye, the new IOLMaster 500 offers the fastest and easiest way of calculating the right IOL for each patient.

Read more...
Alcon acquires LenSx
In its continuing quest to play a part in every step of the cataract procedure Alcon is to acquire LenSx Lasers Inc., for $361.5 million in cash plus maximum contingent payments of $382.5 million based on future revenue targets being achieved and exceeded. The deal will be subject to the required regulatory approvals in the States. More...
RNAi gene silencing technology in form of ophthalmic drops completes Phase 1a clinical trial
In Spain, the first product based on interference RNA (RNAi) technology is an ophthalmic treatment in the form of drops to treat elevated IOP and glaucoma. SYL040012 has just completed its first clinical trial, having been administered to 30 healthy volunteers. More...

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other
opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail
at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom